$183 Million is the total value of Consonance Capital Management LP's 17 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 71.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TNDM | Sell | TANDEM DIABETES CARE INC | $58,177,000 | -39.0% | 487,327 | -50.2% | 31.84% | +177.4% |
| GMED | Sell | GLOBUS MED INCcl a | $45,137,000 | -46.3% | 589,100 | -45.7% | 24.71% | +144.1% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $29,134,000 | +2.1% | 157,838 | -0.8% | 15.95% | +364.3% |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $19,412,000 | -80.4% | 305,994 | -74.5% | 10.62% | -10.7% |
| New | SURROZEN INC | $6,718,000 | – | 1,000,000 | +100.0% | 3.68% | – | |
| SLN | Sell | SILENCE THERAPEUTICS PLCads | $3,729,000 | -35.5% | 178,787 | -19.5% | 2.04% | +193.7% |
| New | ARYA SCIENCES ACQUISITN CORP | $2,964,000 | – | 300,000 | +100.0% | 1.62% | – | |
| RACB | RESEARCH ALLIANCE CORP II | $2,955,000 | -2.5% | 300,000 | 0.0% | 1.62% | +343.0% | |
| JYAC | JIYA ACQUISITION CORP | $2,927,000 | -1.8% | 300,000 | 0.0% | 1.60% | +346.2% | |
| MSAC | MEDICUS SCIENCES ACQUISITION | $2,925,000 | +1.0% | 300,000 | 0.0% | 1.60% | +360.1% | |
| OLK | New | OLINK HLDG ABsponsored ads | $2,799,000 | – | 115,425 | +100.0% | 1.53% | – |
| PANA | PANACEA ACQUISITION CORP II | $1,953,000 | -2.4% | 200,000 | 0.0% | 1.07% | +343.6% | |
| CASI | Sell | CASI PHARMACEUTICALS INC | $1,860,000 | -88.4% | 1,563,003 | -84.9% | 1.02% | -47.1% |
| HLXA | HELIX ACQUISITION CORP | $1,489,000 | -4.1% | 150,000 | 0.0% | 0.82% | +335.8% | |
| New | SURROZEN INC*w exp 08/01/203 | $361,000 | – | 333,333 | +100.0% | 0.20% | – | |
| CMAXW | CAREMAX INC*w exp 06/08/202 | $134,000 | -38.2% | 45,960 | 0.0% | 0.07% | +180.8% | |
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $24,000 | -29.4% | 33,331 | 0.0% | 0.01% | +225.0% | |
| TKNO | Exit | ALPHA TEKNOVA INC | $0 | – | -75,000 | -100.0% | -0.21% | – |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -180,000 | -100.0% | -0.25% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -250,000 | -100.0% | -0.32% | – |
| CMAX | Exit | CAREMAX INC | $0 | – | -213,036 | -100.0% | -0.33% | – |
| CLRB | Exit | CELLECTAR BIOSCIENCES INC | $0 | – | -3,913,000 | -100.0% | -0.56% | – |
| SIOX | Exit | SIO GENE THERAPIES INC | $0 | – | -2,969,987 | -100.0% | -0.98% | – |
| CHFWU | Exit | CONSONANCE HFW ACQUISITION Cunit 99/99/9999 | $0 | – | -1,000,000 | -100.0% | -1.25% | – |
| ACET | Exit | ADICET BIO INC | $0 | – | -1,025,405 | -100.0% | -1.27% | – |
| INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -3,766,817 | -100.0% | -1.36% | – |
| NKTX | Exit | NKARTA INC | $0 | – | -439,876 | -100.0% | -1.68% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -388,222 | -100.0% | -1.71% | – |
| CFMS | Exit | CONFORMIS INC | $0 | – | -12,744,030 | -100.0% | -1.76% | – |
| GMDA | Exit | GAMIDA CELL LTD | $0 | – | -2,858,558 | -100.0% | -2.20% | – |
| AFMD | Exit | AFFIMED N V | $0 | – | -3,176,418 | -100.0% | -3.25% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -409,301 | -100.0% | -3.83% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -887,885 | -100.0% | -4.54% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -13,600,014 | -100.0% | -6.66% | – |
| LEGN | Exit | LEGEND BIOTECH CORPsponsored ads | $0 | – | -1,647,497 | -100.0% | -8.14% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -3,446,874 | -100.0% | -18.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.